Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL15413666 | 0.98 | CYP11B2 (0.46) | CYP11B2CYP11B1PRKCZADRA2AADRA2B | |
| SCHEMBL28005981 | 0.84 | CYP11B2 (0.45) | CYP11B2CYP11B1PRKCZADRA2AADRA2B | |
| SCHEMBL2258454 | 0.81 | CYP11B1 (0.49) | CYP11B2CYP11B1PRKCZADRA2AADRA2B | |
| SCHEMBL9646280 | 0.79 | CYP11B2 (0.47) | CYP11B2CYP11B1PRKCZADRA2AADRA2B | |
| SCHEMBL3822233 | 0.79 | CYP11B2 (0.47) | CYP11B2CYP11B1PRKCZADRA2AADRA2B | |
| SCHEMBL25076210 | 0.79 | CYP11B2 (0.47) | CYP11B2CYP11B1PRKCZADRA2AADRA2B | |
| SCHEMBL4045763 | 0.79 | CYP11B1 (0.47) | CYP11B2CYP11B1PRKCZADRA2AADRA2B | |
| SCHEMBL873335 | 0.79 | CYP11B1 (0.47) | CYP11B2CYP11B1PRKCZADRA2AADRA2B | |
| SCHEMBL9572666 | 0.79 | CYP11B2 (0.47) | CYP11B2CYP11B1PRKCZADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL6845329 | 0.79 | CYP11B1 (0.47) | CYP11B2CYP11B1PRKCZADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922407-A | Respiratory Syncytial Virus(RSV) inhibitor | 美迪维尔公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-107428692-A | Substituted monoazanaphthalene derivatives and polyazanaphthalene derivatives and use thereof | 巴斯利尔药物国际股份公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-104507913-B | The antiproliferative ketone of benzo [b] azepine * 2 | 霍夫曼-拉罗奇有限公司 | 2017-07-28 | — | — | CN | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
| US-9040538-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITE LAVAL (CA) | 2015-05-26 | — | — | US | disclosed |
| US-9040538-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITE LAVAL (CA) | 2015-05-26 | — | — | US | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| WO-2010132999-A1 | METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | CHLORION PHARMA, INC. (CA) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | CYP11B2 117/4885CYP11B1 204/4885PRKCZ 2148/4885 |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | CYP11B2 117/4885CYP11B1 204/4885PRKCZ 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.